Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 23, 2017
Pharmacy Choice - News - Pharmaceutical Development - September 23, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/22/17 - AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
NORTH CHICAGO, Ill. and NEW YORK, Sept. 22, 2017/ PRNewswire/ AbbVie and Bristol-Myers Squibb Company today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo in c-Met overexpressing non-small cell lung cancer.
9/22/17 - Addition to Moberg Pharma's management team
STOCKHOLM, September 22nd 2017, Moberg Pharma AB appoints Torbjrn Wrnheim, Director Pharmaceutical Innovation and Development, as a member of Moberg's Management Team, effective from today. Torbjrn Wrnheim has had this position at Moberg Pharma since 2013.. I look forward to keep working together to continue to progress our development prog
9/22/17 - Aeolus Announces Presentation of Pharmacometric Analysis of Data Establishing Optimal Dose Schedule of AEOL 10150 for Treatment of Lung Radiation Damage
MISSION VIEJO, CA/ ACCESSWIRE/ September 22, 2017/ Aeolus Pharmaceuticals, Inc., a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today presentation of pharmacometric-based analysis confirming the optimal dosing schedule for AEOL 10150 in the treatment of the pulmonary...
9/22/17 - Aeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting Officer
By a News Reporter-Staff News Editor at Drug Week Aeterna Zentaris Inc. announced the departure of the Company's Vice President, Finance& Chief Accounting Officer, Genevieve Lemaire, effective on or before September 30, 2017. About Aeterna Zentaris Inc. Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercial
9/22/17 - Agilent Technologies Receives Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer
Agilent Technologies Inc. today announced its Dako PD-L1 IHC 22 C3 pharmDx assay has an expanded label approved by U.S. Food and Drug Administration, for use as an aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDA , an anti-PD-1 therapy manufactured by Merck& Co., Inc., Kenilworth, N.J., USA. First approved by
9/22/17 - Allergan Receives Refusal to File Letter from FDA for Vraylar (cariprazine) Supplemental New Drug Application (sNDA) for the Treatment of Negative Symptoms in Schizophrenia
Allergan plc today announced that it received a Refusal to File letter from the U.S. Food and Drug Administration regarding its Supplemental New Drug Application for Vraylar for treatment of negative symptoms associated with schizophrenia in adult patients. Upon its preliminary review, FDA determined that the sNDA for treatment of negative sympto
9/22/17 - Alligator Bioscience to Present ADC-1013 Intratumoral Clinical Phase I Study Results at SITC in November 2017 [Sport360]
Alligator Bioscience, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that results from a clinical phase I study of the drug candidate ADC-1013 will be presented at the Society for Immunotherapy of Cancer 32nd Annual Meeting, held from 8-12 November 2017 at the Gaylord National...
9/22/17 - Alnylam takes off on APOLLO trial results [All Iraq News Agency (AIN)]
Armed with the new data, Alnylam and its partner for patisiran Sanofi say they hope to file for approval of the gene-silencing drug before the end of the year, with an EU filing due a little later in 2018.. Roche`s decision to exit the field some years back dampened enthusiasm, but smaller players such as Alnylam have stuck with the technology and
9/22/17 - Amerigen believes that it is a first applicant to file an Abbreviated New Drug Application "ANDA" for certain strengths of Namzaric containing a...
By a News Reporter-Staff News Editor at Drug Week Amerigen Pharmaceuticals Limited announced that, based on the August 7th, 2017 update to the U.S. Food& Drug Administration's online databasea, the Company believes that it is a first applicant to file an Abbreviated New Drug Application for Namzaric 7/ 10 b and 21/ 10 c containing a "Paragraph
9/22/17 - ANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL
By a News Reporter-Staff News Editor at Drug Week ANI Pharmaceuticals, Inc. announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Oxycodone Hydrochloride Oral Solution USP, 100 mg/5 mL. The current annual U.S. market for this product is approximately $14.5 million, according
9/22/17 - Aquavit's iMicrotox IMX-001 Study Receives IRB Approval
By a News Reporter-Staff News Editor at Health& Medicine Week Aquavit Pharmaceuticals announced that it has received a green light from the IRB, to conduct in-depth research for microchannel application of neurotoxins in the peri-orbital region. This study includes the three currently FDA approved neurotoxins to be administered through AQT-001,..
9/22/17 - Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26
Aradigm Corporation today announced that Aradigm management will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017, at 2:00 p.m. ET. Aradigm has completed two Phase 3 clinical trials with Linhaliq?, an investigational proprietary formulation of ciprofloxacin for inhalation, for the treatment of NCFBE and.
9/22/17 - Biotech Movers: Versartis, Inc. (NASDAQ:VSAR) and Intercept Pharmaceuticals Inc (NASDAQ:ICPT)
It has been a tough close to the week for a number of biotech companies. Disappointing clinical trial data, as well as some unexpected input from the US Food and Drug Administration (FDA), has dominated the news in the space and the companies affected have taken a hit as a result. Here are the two [?] The post Biotech Movers: Versartis, Inc. (NAS
9/22/17 - Bioventus Receives US FDA Approval for DUROLANE
By a News Reporter-Staff News Editor at Health& Medicine Week Bioventus, a global leader in orthobiologic solutions, announced it has received US FDA approval for DUROLANE, a single-injection, hyaluronic acid product used for joint lubrication in the treatment of pain associated with knee osteoarthritis. "More than 20 million Americans are affli
9/22/17 - Blacksburg firm snags funding Blacksburg biotech snags $10 million investment to push new drug into clinical trials
Landos Biopharma, a new Blacksburg startup, burst out of the gate on Thursday with $10 million in venture funding to begin clinical trials of a potentially breakthrough drug. The company was founded earlier this year by Virginia Tech's Josep Bassaganya-Riera, a researcher with a track record of spinout companies. Landos launched earlier this year a
9/22/17 - Blacksburg firm snags funding
Landos Biopharma, a new Blacksburg startup, burst out of the gate on Thursday with $10 million in venture funding to begin clinical trials of a potentially breakthrough drug. The company was founded earlier this year by Virginia Tech's Josep Bassaganya-Riera, a researcher with a track record of spinout companies. Landos launched earlier this year a
9/22/17 - BMS wins NICE reversal, Opdivo granted second-line lung cancer approval [Syrian Arab News Agency]
Bristol-Myers Squibb finally discovered the password to get NICE to open the gates to the kingdom for Opdivo as a treatment for lung cancer: managed access agreement. Englands drug cost gatekeeper today agreed to fund the immuno-oncology drug as a second line treatment for lung cancer through the countrys cancer drug fund, but under strict conditio
9/22/17 - Bristol-Myers Squibb's Opdivo (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib
Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration has approved Opdivo injection for intravenous use for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib. We are proud to bring the potential for clinically meaningful responses with Immuno-Oncology therapy to..
9/22/17 - Cancer biobank Indivumed and CRO Helomics team up on precision medicine [Arab Finance (Egypt)]
Indivumed, which has a large cancer biobank, has partnered with cancer research specialist Helomics to analyze human cancer biospecimens and relevant clinical data collected from patients around the world to help advance research in personalized cancer treatments. Its clinical network includes hospitals and clinics in Germany, Poland, the U.S. and
9/22/17 - CORRECTING and REPLACING Agilent Technologies Receives Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer
Agilent Technologies Inc. today announced its Dako PD-L1 IHC 22 C3 pharmDx assay has an expanded label approved by U.S. Food and Drug Administration, for use as an aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDA , an anti-PD-1 therapy manufactured by Merck& Co., Inc., Kenilworth, N.J., USA. The FDA also annou
9/22/17 - CTD Holdings to Present at UK Annual Conference for NPC Patients, Families and Caregivers
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the company will present on its clinical and drug development program for the orphan drug, Trappsol Cyclo?, at the Niemann-Pick UK 8 th Interactive Workshop on Niemann-P
9/22/17 - Dova Pharmaceuticals Announces New Drug Application Submission to FDA for Avatrombopag, a Second Generation Thrombopoietin Receptor Agonist
Dova Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for avatrombopag, a second generation orally administered thrombopoietin receptor agonist for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled t
9/22/17 - DOVA PHARMACEUTICALS, INC. FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
On September 22, 2017, Dova Pharmaceuticals, Inc. issued a press release announcing the submission of a new drug application to the U.S. Food and Drug Administration for avatrombopag. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8- K, the contents of which are incorporated herein by reference. Exhibits Exh
9/22/17 - Dr Reddy`s CPS facility clears USFDA audit; shares zoom over 7% [Arab Times (Kuwait)]
The Custom Pharmaceutical Services facility of Dr Reddys Laboratories Ltd at its Technology Development Centre, Miyapur here has cleared the US Food and Drug Administration audit. The audit of the facility "has been completed today with zero observations``, the Hyderabad- based company informed the bourses in an update on Thursday. Dr Reddys scrip
9/22/17 - E Clinical Solution Market Is Projected to Reflect 13.8% CAGR Throughout 2014-2020
The global e-clinical solution software market is witnessing significant growth due to increasing clinical trials and R&D investments in pharmaceuticals and life science sectors.New York, NY 09/22/2017 According to a new market report published by Persistence Market Research "Global Market Study on E-Clinical Solution Software: Asia to Witnes
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415